pleased strategies growth our opportunity market the We've on fronts GX Leigh. utilization. and for we are progress base to important in am made multiple the us. you, our and and of installed on of positively expand all executing patients team with first you joining the over I with solid glaucoma. our Good increased thank year three which believe impacting treating performance quarters trajectory Thank afternoon, significant this
million the turn to and quarter call few are in on the included premier around guidance the U.S. in accessory to physician minutes increase significant the Advancements provide particularly probe to our We to true to updated FDA to and $XX.X summary, revenues to Laser LIO probe and for the progress awareness presentations in probes team of our and our for systems XX% clearance for capital world. increase of number quarter growth. the a this our $XX.X some out like GX on investments GX fund gross Total including we'll development commercial our shipments. continued the year-over-year revenues next to third financials in made take in introduce beginning building million, for realize GX and A platform to acceptance our year. cover markets. over the technology. with benefits color MicroPulse business. Atabak third momentum In business were focus then I'd raise proceeds of GX
are Our third quarter doctors by and given results schedules. typically summer impacted vacation seasonality patients
GX growth one our XXXX our However, shipments as probe is quarter, the GX awareness systems clearance we retina to GX and updated across GXs the primary to of and Key In commercial third globe. more and of goals utilization we growth in Since following than GX nukes systems and XXX platform. our of GX continuing business our we in LIO, specifically while we more shipments. base March the both year-over-year business our drive with shipped existing performance were XXXX installed pleased laser span the to of from strategy continued acceptance the of were well XXX,XXX and have the our FDA our in XXXX accessory. U.S. successful systems for launch probes. improve our probe XX,XXX team as More to shipped Geographically, achieving GX probes. in than systems
consistent shipments a Early now outcomes. service several delivered our has ensure we been towards education more training third feedback been of year. positive strengthening on in and cadence have field has In in the relationships enhance that training throughout customer steady also team key consistent clinical quarter We supporting specialists very this GX the and sales the to with to existing accounts. program better position systems
On probe impacted grew seasonality. shipments the a year-over-year was but side by QX
of in hospitals and and progress in the patients patients treating am earlier trending of glaucoma XX in strength continued ophthalmology I continuum However, ranked of care. particularly the proud treating that we U.S. encouraged by excuse me, by GX XX U.S. the the stage late best the as
impacts KOL the despite growing regarding the partner. support. Report and in three organization and and the customers. delivered well sales World Internationally, foundation in teams sets Japan, be the to even our in GX are attributed serving second pronounced In probe GX for we recently countries. their support large KOL which with further a excellent and several a KOLs this believe marketing for benefits nice More to approval Record all reps strong region. be In hospitals can sales are in for in a selling solid quarter more progress in region GX specifically GX we We is ongoing shipments distribution continues News been Korea in and this made this as we to strong I'm of Overall as U.S. which as with the first of KOL pleased penetration are sales made to fronts systems us performance direct a and making clinical selling Germany, model to pleased expansion already and improvements which activities realized nice progress on investment sales systems market. cover seasonality particular number region. we're quarter other GX large and South we the Korea, presented. our has have in progress. made expanded we In achieve in the paper and in progress including
stages front of treating glaucoma. a world to the key to marketing the events our we awareness benefits maintain at all the raise of of significant around presence technology On continue MicroPulse industry in
and see procedure with signaling disease in the to to our GX ophthalmologists starting stage of treating the are to comprehensive among patients, awareness the treatment stage glaucoma. of a growing versatility advocating we to moderate earlier Importantly, extend support use for patients
As this in earlier expect utilization. traction drive stage we we gain treatments further to
booth had At particularly countries and During we meeting the Also that AAO. training AAO had at we show significant symposium AAO presence proctored largest presence featuring over from XXX the included globe ESCRS this a XXX ESCRS of attendees the XX recent glaucoma exceptional lab also train QX on-site. globe hosted panel doctors hosted around We the trade with multiple we GX across in that the meeting over official dry to and and trade a courses. discussions ESCRS at were we two physicians included attendees. in shows. and
as to activity nice perspective clinical have our positive key of posters pleased events. papers, the proposition of with value a sentiment this GX. From cadence and support very are growing clinical the towards continue We that we a products studies, these
new Over the eyes that in were were at AAO and publications posters two the presented two reviewed that international eyes. journals XX last few XX reviewed months peer-reviewed respected there
the care which physician changing of lives continuing in presented AAO their population. believe GX the the we I'm that the around patients. are how customers our posters regarding from One the data important meaningfully our we the seeing patients earlier the migrate of world especially as growing of this is treatment patient of is support we and proud treating towards
particular, these improve additional we outcomes. entire the product I nearing enhancement On use to on features next completion the reduce availability and are made able cost. and In share ease improve front detail that the by of in consistent expect be several portfolio early progress product to provide quality, GX will advancements across have on our timing advancements to of year. design probe and more we
LIO they to the expected orders revenues. we us to laser noted clearance updated Internationally, from through to pull clearance related orders. our take customers of in U.S. that our are received and some fulfill we pleased forward to allowed to have products Turning premier voluntary August fulfill backlog fulfilled include The retina introduce LIO as recall FDA new U.S. distributed you large our GX late the market. earlier accessory focus to and
remains meaningful to contributor current business a our retina Our revenue.
on this products as sales continue we treatment overall focus of been retina to stabilizing continue intended for GX line business. growth of business products our We have However, for work longer towards to not term. of glaucoma, to driver the sales a
a Grove board who to He to the turn excellent perfect spent his this is like Dr. be our Bob of to I welcome month. Before the results extensive fit and us for career joined medicine will Robert and an addition. I for both of detail success technologies. officially directors Atabak has call repeated based the turn over and board would our to Atabak I'd to quarter has guidance in point, like and the laser over Atabak? financial XXXX. At provide further field novel laser of call this for commercializing our to developing
